<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on 24 patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> (19 pts), <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorders</z:e> (4 pts) or severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 cases </plain></SENT>
<SENT sid="2" pm="."><plain>Preparative regimens were in accord with standards for diagnosis and disease status and included TBI in 15 patients, <z:chebi fb="0" ids="28901">busulfan</z:chebi> in 8, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> alone in one patient with SAA </plain></SENT>
<SENT sid="3" pm="."><plain>GvHD prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>/<z:chebi fb="0" ids="44185">methotrexate</z:chebi> in the majority of cases; 6 patients received additional immunotherapy with anti-lymphocyte globulin and 1 patient in vivo Campath-1G </plain></SENT>
<SENT sid="4" pm="."><plain>The bone marrow was T-cell depleted in 2 cases </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GvHD grade II-IV occurred in 87% of patients (gr.III-IV: 57%) and was the main cause of <z:hpo ids='HP_0011420'>death</z:hpo> in 8 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients (25%) survive with a median follow-up of 9 months, (16% actuarial survival at 3 years) </plain></SENT>
<SENT sid="7" pm="."><plain>A trend in favour of a better outcome has been found for age &lt; 20 yrs at BMT (33% vs 22%), intensified GvHD prophylaxis (33% vs 22%) and transplants performed in more recent years (31% vs 18%) </plain></SENT>
</text></document>